

# Frank H J Van Den Hoogen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7680967/publications.pdf>

Version: 2024-02-01

107  
papers

10,728  
citations

109137

35  
h-index

33814

99  
g-index

109  
all docs

109  
docs citations

109  
times ranked

10524  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study. <i>Rheumatology</i> , 2022, 61, 2307-2315.	0.9	14
2	Economic evaluation of the dr. Bart app in people with knee and/or hip osteoarthritis. <i>Arthritis Care and Research</i> , 2021, , .	1.5	3
3	Use and usability of the dr. Bart app and its relation with health care utilisation and clinical outcomes in people with knee and/or hip osteoarthritis. <i>BMC Health Services Research</i> , 2021, 21, 444.	0.9	4
4	Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets. <i>Journal of Rheumatology</i> , 2021, 48, jrheum.201594.	1.0	6
5	Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER): Protocol for a Longitudinal Observational Study. <i>JMIR Research Protocols</i> , 2021, 10, e31647.	0.5	3
6	Polymyalgia rheumatica patients with and without elevated baseline acute phase reactants: distinct subgroups of polymyalgia rheumatica?. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 32-37.	0.4	4
7	Response to: 'Effectiveness of low-dose radiation therapy on symptoms in patients with knee osteoarthritis' by Wu et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e25-e25.	0.5	1
8	Response to: 'Is it time to redefine the role of low-dose radiotherapy for benign disease?' by Montero et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e35-e35.	0.5	0
9	Interventions to support shared decision making for medication therapy in long term conditions: A systematic review. <i>Patient Education and Counseling</i> , 2020, 103, 254-265.	1.0	21
10	Treatment with cyclophosphamide i.v. pulse therapy is an option for effective treatment of skin fibrosis in patients with early systemic sclerosis. <i>Rheumatology</i> , 2020, 59, 1550-1555.	0.9	8
11	Comparison of physical activity among different subsets of patients with knee or hip osteoarthritis and the general population. <i>Rheumatology International</i> , 2020, 40, 383-392.	1.5	8
12	Short fatigue questionnaire: Screening for severe fatigue.. <i>Journal of Psychosomatic Research</i> , 2020, 137, 110229.	1.2	17
13	Preparing for an orthopedic consultation using an eHealth tool: a randomized controlled trial in patients with hip and knee osteoarthritis. <i>BMC Medical Informatics and Decision Making</i> , 2020, 20, 92.	1.5	9
14	Systemic sclerosis: To subset or not to subset, that is the question. <i>European Journal of Rheumatology</i> , 2020, 7, 222-227.	1.3	13
15	Effectiveness of low-dose radiation therapy on symptoms in patients with knee osteoarthritis: a randomised, double-blinded, sham-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, annrheumdis-2018-214104.	0.5	43
16	Most Important Frequently Asked Questions From Patients With Hip or Knee Osteoarthritis: A Best Worst Scaling Exercise. <i>Arthritis Care and Research</i> , 2019, 71, 885-892.	1.5	10
17	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. <i>Rheumatology</i> , 2019, , .	0.9	0
18	SAT0259: PREDICTIVE FACTORS FOR TREATMENT RELATED MORTALITY AND MAJOR ADVERSE EVENTS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS: RESULTS OF A LONG TERM FOLLOW-UP MULTI-CENTRE STUDY. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
19	SAT0282â€¦EFFICACY AND SAFETY OF ORAL PROSTACYCLIN RECEPTOR AGONIST SELEXIPAG IN PATIENTS WITH SYSTEMIC SCLEROSIS -ASSOCIATED PULMONARY ARTERIAL HYPERTENSION IN DAILY CLINICAL PRACTICE, A CASE SERIES. , 2019, , .		0
20	OP0079â€¦HPR NON-PHARMACOLOGICAL CARE IN SYSTEMIC SCLEROSIS: OPENING THE BLACK BOX. , 2019, , .		0
21	An Electronic Health Tool to Prepare for the First Orthopedic Consultation: Use and Usability Study. JMIR Formative Research, 2019, 3, e13577.	0.7	6
22	Short-term clinical worsening is a clear predictor for worsening at 2 years in established knee and hip osteoarthritis. Clinical and Experimental Rheumatology, 2019, 37, 414-421.	0.4	0
23	Predictive value of ex-vivo drug-inhibited cytokine production for clinical response to biologic DMARD therapy in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2019, 37, 367-372.	0.4	1
24	Openâ€Label, Nonâ€Mandatory Transitioning From Originator Etanercept to Biosimilar <sc>SB</sc>4. Arthritis and Rheumatology, 2018, 70, 1408-1418.	2.9	90
25	Treatment Beliefs Underlying Intended Treatment Choices in Knee and Hip Osteoarthritis. International Journal of Behavioral Medicine, 2018, 25, 198-206.	0.8	12
26	Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Openâ€Label Transition From Reference Infliximab to Biosimilar Infliximab. Arthritis and Rheumatology, 2018, 70, 60-68.	2.9	142
27	Patient Acceptable Symptom State in Knee Osteoarthritis Patients Succeeds Across Different Patient-reported Outcome Measures Assessing Physical Function, But Fails Across Other Dimensions and Rheumatic Diseases. Journal of Rheumatology, 2018, 45, 122-127.	1.0	10
28	What moves the rheumatologist? Unravelling decision making in the referral of systemic sclerosis patients to health professionals: a qualitative study. Rheumatology Advances in Practice, 2018, 2, rky027.	0.3	6
29	Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity. Frontiers in Immunology, 2018, 9, 2388.	2.2	21
30	Unraveling SSc Pathophysiology; The Myofibroblast. Frontiers in Immunology, 2018, 9, 2452.	2.2	103
31	Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent. BioDrugs, 2018, 32, 397-404.	2.2	82
32	Support needs for medication use and the suitability of eHealth technologies to address these needs: a focus group study of older patients with rheumatoid arthritis. Patient Preference and Adherence, 2018, Volume 12, 349-358.	0.8	19
33	Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trial. Trials, 2018, 19, 449.	0.7	14
34	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology, 2018, 57, 1623-1631.	0.9	53
35	Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis. RMD Open, 2018, 4, e000654.	1.8	28
36	Ex vivo inhibited cytokine profiling may explain inferior treatment response to golimumab after adalimumab failure in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2018, 36, 140-143.	0.4	1

#	ARTICLE	IF	CITATIONS
37	Milk-Derived Nanoparticle Fraction Promotes the Formation of Small Osteoclasts But Reduces Bone Resorption. <i>Journal of Cellular Physiology</i> , 2017, 232, 225-233.	2.0	36
38	What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?. <i>RMD Open</i> , 2017, 3, e000327.	1.8	6
39	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. <i>Rheumatology</i> , 2017, 56, 1302-1311.	0.9	51
40	A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes. <i>Rheumatology</i> , 2017, 56, 973-980.	0.9	20
41	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.5	794
42	Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review. <i>Arthritis and Rheumatology</i> , 2017, 69, 301-308.	2.9	56
43	Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 403.	0.7	18
44	Evolving Concepts of Diagnosis and Classification. , 2017, , 49-64.		2
45	Three-year trajectories of disability and fatigue in systemic sclerosis: a cohort study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 48-55.	0.4	2
46	Suppression of the inflammatory response by disease-inducible interleukin-10 gene therapy in a three-dimensional micromass model of the human synovial membrane. <i>Arthritis Research and Therapy</i> , 2016, 18, 186.	1.6	21
47	High-Dose Intravenous Pulse Methotrexate in Patients With Eosinophilic Fasciitis. <i>JAMA Dermatology</i> , 2016, 152, 1262.	2.0	19
48	Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study. <i>Rheumatology</i> , 2016, 55, 2001-2008.	0.9	34
49	An easy prediction rule for diffuse cutaneous systemic sclerosis using only the timing and type of first symptoms and auto-antibodies: derivation and validation. <i>Rheumatology</i> , 2016, 55, 2023-2032.	0.9	9
50	Cost-Utility and Cost-Effectiveness Analyses of Face-to-Face Versus Telephone-Based Nonpharmacologic Multidisciplinary Treatments for Patients With Generalized Osteoarthritis. <i>Arthritis Care and Research</i> , 2016, 68, 502-510.	1.5	18
51	Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2260-2261.	0.5	15
52	Specificity of Systemic Sclerosis Classification Criteria. <i>Journal of Rheumatology</i> , 2015, 42, 2512-2512.	1.0	3
53	Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. <i>BMJ</i> , The, 2015, 350, h1389-h1389.	3.0	135
54	(Bi)Weekly folic acid supplementation might be inferior to a daily folic acid dosing schedule in the prevention of methotrexate-related toxicity in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 767-8.	0.4	1

#	ARTICLE	IF	CITATIONS
55	Cognitive-Behavioural Therapy Targeting Fear of Progression in an Interdisciplinary Care Program: A Case Study in Systemic Sclerosis. <i>Journal of Clinical Psychology in Medical Settings</i> , 2014, 21, 297-312.	0.8	4
56	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 706-714.	2.4	52
57	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatism</i> , 2013, 65, 2737-2747.	6.7	2,359
58	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1747-1755.	0.5	1,705
59	The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non)response to infliximab in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 939-945.	1.1	32
60	Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study. <i>BMC Musculoskeletal Disorders</i> , 2013, 14, 299.	0.8	39
61	Cross-Language Measurement Equivalence of the Center for Epidemiologic Studies Depression (CES-D) Scale in Systemic Sclerosis: A Comparison of Canadian and Dutch Patients. <i>PLoS ONE</i> , 2013, 8, e53923.	1.1	14
62	Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1849-1854.	0.5	88
63	Disease-related and psychosocial factors associated with depressive symptoms in patients with systemic sclerosis, including fear of progression and appearance self-esteem. <i>Journal of Psychosomatic Research</i> , 2012, 72, 199-204.	1.2	54
64	Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study. <i>BMC Musculoskeletal Disorders</i> , 2012, 13, 184.	0.8	25
65	Evolving Concepts of Diagnosis and Classification. , 2012, , 53-69.		2
66	Development and content of a group-based intervention to improve medication adherence in non-adherent patients with rheumatoid arthritis. <i>Patient Education and Counseling</i> , 2012, 89, 143-151.	1.0	17
67	Validity of the Fear of Progression Questionnaire—Short Form in patients with systemic sclerosis. <i>Arthritis Care and Research</i> , 2012, 64, 930-934.	1.5	34
68	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. <i>Arthritis Care and Research</i> , 2012, 64, 351-357.	1.5	49
69	Validation of potential classification criteria for systemic sclerosis. <i>Arthritis Care and Research</i> , 2012, 64, 358-367.	1.5	77
70	Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusion cycle: an open-label pharmacokinetic cohort study. <i>BMC Musculoskeletal Disorders</i> , 2011, 12, 12.	0.8	35
71	Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2011, 63, 775-782.	6.7	86
72	Fatigue in knee and hip osteoarthritis: the role of pain and physical function. <i>Rheumatology</i> , 2011, 50, 1894-1900.	0.9	41

#	ARTICLE	IF	CITATIONS
73	The effects of doxycycline on reducing symptoms in knee osteoarthritis: results from a triple-blinded randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1191-1196.	0.5	32
74	Analysis of 4-year Dutch reimbursement application data of biological therapies for psoriatic arthritis. <i>Rheumatology</i> , 2010, 49, 588-591.	0.9	5
75	Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1655-1659.	0.5	10
76	Poor psychological health status among patients with inflammatory rheumatic diseases and osteoarthritis in multidisciplinary rehabilitation: Need for a routine psychological assessment. <i>Disability and Rehabilitation</i> , 2010, 32, 836-844.	0.9	28
77	Functional Variants of Fc Gamma Receptor (FCGR2A) and FCGR3A Are Not Associated with Susceptibility to Systemic Sclerosis in a Large European Study (EUSTAR). <i>Journal of Rheumatology</i> , 2010, 37, 1673-1679.	1.0	9
78	Treatment of the inflammatory myopathies: update and practical recommendations. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1183-1190.	0.9	47
79	Circulating Leptin and Adiponectin Concentrations During Tumor Necrosis Factor Blockade in Patients with Active Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 724-730.	1.0	68
80	Effect of naproxen on the hypothalamic-pituitary adrenal axis in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 22-28.	1.1	6
81	Adherence Rates and Associations with Nonadherence in Patients with Rheumatoid Arthritis Using Disease Modifying Antirheumatic Drugs. <i>Journal of Rheumatology</i> , 2009, 36, 2164-2170.	1.0	120
82	The -2518A>G promoter polymorphism in the CCL2 gene is not associated with systemic sclerosis susceptibility or phenotype: Results from a multicenter study of European Caucasian patients. <i>Human Immunology</i> , 2009, 70, 130-133.	1.2	9
83	Total ankle prostheses in rheumatoid arthropathy. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2009, 80, 440-444.	1.2	52
84	Social Support, Disease-Related Cognitions and Coping as Predictors of Depressed Mood in Systemic Sclerosis. <i>Cognitive Therapy and Research</i> , 2008, 32, 434-447.	1.2	7
85	Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. <i>Arthritis and Rheumatism</i> , 2008, 59, 699-705.	6.7	109
86	Survivorship of the KUDO total elbow prosthesis comparative study of cemented and uncemented ulnar components: 89 cases followed for an average of 6 years. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2007, 78, 258-262.	1.2	32
87	Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1503-1507.	0.5	136
88	What does the clinician need to improve patient care in systemic sclerosis?. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1129-1131.	0.5	2
89	Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor A-neutralising treatments in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1525-1530.	0.5	13
90	Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1334-1338.	0.5	26

#	ARTICLE	IF	CITATIONS
91	Recombinant human anti- $\alpha$ -transforming growth factor $\beta$ 1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. <i>Arthritis and Rheumatism</i> , 2007, 56, 323-333.	6.7	415
92	Eosinophilic fasciitis in a child mimicking a myopathy. <i>Neuromuscular Disorders</i> , 2006, 16, 144-148.	0.3	30
93	Improved insulin sensitivity by anti-TNF $\alpha$ antibody treatment in patients with rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 558-559.	0.5	70
94	InforMatrix $\text{\textcircled{R}}$ : treatment of rheumatoid arthritis using biologicals. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1769-1789.	0.9	3
95	Mortality in systemic sclerosis: An international meta-analysis of individual patient data. <i>American Journal of Medicine</i> , 2005, 118, 2-10.	0.6	419
96	Anti-cyclic citrullinated peptide antibody in early rheumatoid arthritis: Comment on the editorial by Scott. <i>Arthritis and Rheumatism</i> , 2003, 48, 857-857.	6.7	1
97	Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. <i>Arthritis Research</i> , 2002, 4, 87.	2.0	303
98	Identity of the RNase MRP- and RNase P-associated Th/To autoantigen. <i>Arthritis and Rheumatism</i> , 2002, 46, 3266-3272.	6.7	54
99	High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: Results of an open study to assess feasibility, safety, and efficacy. <i>Arthritis and Rheumatism</i> , 2001, 44, 754-760.	6.7	110
100	The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. <i>Arthritis and Rheumatism</i> , 2000, 43, 155-163.	6.7	1,250
101	The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2000, 43, 1831-1835.	6.7	573
102	Systemic Sclerosis: New Insights in Autoimmunity. <i>Proceedings of the Society for Experimental Biology and Medicine</i> , 1999, 222, 1-8.	2.0	6
103	Nontuberculous mycobacterial bursitis and arthritis of the shoulder. <i>Skeletal Radiology</i> , 1998, 27, 33-35.	1.2	42
104	Shoulder hemiarthroplasty in rheumatoid arthritis 19 cases reexamined after 1-17 years. <i>Acta Orthopaedica</i> , 1997, 68, 243-245.	1.4	29
105	Isolation and Characterization of Single Anti-U1A-specific B Cells from Autoimmune Patients. <i>Annals of the New York Academy of Sciences</i> , 1997, 815, 440-442.	1.8	3
106	Analysis of anti-U1 RNA antibodies in patients with connective tissue diseases: Comment on the article by Hoffman et al. <i>Arthritis and Rheumatism</i> , 1996, 39, 1265-1266.	6.7	0
107	The mutations in the fibronectin gene described in Japanese patients with systemic sclerosis are not present in Dutch patients. <i>Arthritis and Rheumatism</i> , 1991, 34, 490-492.	6.7	3